Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults

• Published in: International clinical psychopharmacology Vol. 28; no. 2; p. 99
• Main Authors: Nichols, Alice I, Abell, Madelyn, Madelyn, Abell, Chen, Yang, Behrle, Jessica A, Frick, Glen, Paul, Jeffrey
• Format: Journal Article
• Language: English
• Published: England 01.03.2013
• Subjects: Adolescent; Adult; Antidepressive Agents - administration & dosage; Antidepressive Agents - adverse effects; Antidepressive Agents, Tricyclic - adverse effects; Antidepressive Agents, Tricyclic - blood; Antidepressive Agents, Tricyclic - pharmacokinetics; Antidepressive Agents, Tricyclic - urine; Biological Availability; Cyclohexanols - administration & dosage; Cyclohexanols - adverse effects; Cytochrome P-450 CYP2D6 - genetics; Cytochrome P-450 CYP2D6 - metabolism; Cytochrome P-450 CYP2D6 Inhibitors; Desipramine - adverse effects; Desipramine - analogs & derivatives; Desipramine - blood; Desipramine - pharmacokinetics; Desipramine - urine; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors - administration & dosage; Enzyme Inhibitors - adverse effects; Female; Half-Life; Humans; Male; Metabolic Clearance Rate; Metabolic Detoxication, Phase I; Middle Aged; Neurotransmitter Uptake Inhibitors - administration & dosage; Neurotransmitter Uptake Inhibitors - adverse effects; Polymorphism, Genetic; Young Adult
• ISSN: 1473-5857
• DOI: 10.1097/YIC.0b013e32835c1f49

The results of two single-center, two-period, open-label trials that evaluated the effects of multiple doses of desvenlafaxine on the pharmacokinetics of desipramine, a cytochrome P450 (CYP) 2D6 enzyme substrate, are presented. Healthy individuals aged 18-45 years were administered a single oral dos...